Erratum to FDA Briefing Document

Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)

June 17, 2022

This erratum contains corrections to FDA's briefing information for the June 17, 2022 PDAC Meeting. The committee will discuss supplemental new drug applications 210793-s008 and 207318-s011, efficacy supplement resubmission for NUPLAZID (pimavanserin) tablets, submitted by Acadia Pharmaceuticals Inc., for the proposed treatment of hallucinations and delusions associated with Alzheimer's disease psychosis.

1) **Page 65, second paragraph, last sentence**

"Pimavanserin $AUC_{0\text{-}24h}$ was calculated using information on daily dose from the start of DB period to the last dose in OL period.

Revised text (deletions in strikethrough font and additions in bolded and underlined font):

"Pimavanserin $AUC_{0\text{-}24h}$ was calculated using information on daily dose from the start of **the OL**~~DB~~ period to the last dose **of the DB**~~in OL~~ period."